T. Rowe Price Associates
SGP

T. Rowe Price Associates’s SpyGlass Pharma SGP Stock Holding History

T. Rowe Price Associates’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.3M Buy
+704,440
New +$19M ﹤0.01% 1072

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

T. Rowe Price Associates's SGP Position: Q1 2026 in Review

T. Rowe Price Associates opened a new position in SpyGlass Pharma (SGP) in Q1 2026: 704,440 shares worth $18.3M. The stake represents ﹤0.01% of the portfolio and ranks #1072 among its holdings.

35 funds tracked by Wall St. Rank hold SGP as of Q1 2026.

  • T. Rowe Price Associates held 704,440 shares of SpyGlass Pharma worth $18.3M as of Q1 2026.
  • SpyGlass Pharma was a new T. Rowe Price Associates position in Q1 2026.
  • SpyGlass Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1072 holding.
  • 35 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.